3F8

3F8 ^?
Monoclonal antibody
Source	Mouse
Target	GD2
Clinical data
Pregnancy cat.	?
Legal status	?
Routes	intravenous
Identifiers
ATC code	None
Chemical data
Formula	?
Y(what is this?) (verify)

3F8 is a murine IgG3^[1] monoclonal antibody which binds to GD2.^[2]

It has been used in the detection and treatment of neuroblastoma. For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131.^[3]^[4]^[5]

References

^ Kushner BH, Cheung NK (1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood 73 (7): 1936–41. PMID 2653466. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=2653466.
^ "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". http://www.mskcc.org/mskcc/html/3215.cfm#261335. Retrieved 2008-02-19.
^ "ACS :: New Drug Targets Tough
Childhood Cancer". http://www.cancer.org/docroot/NWS/content/NWS_1_1x_New_Drug_Targets_Tough_Childhood_Cancer.asp. Retrieved 2008-02-19.
^ Yeh SD, Larson SM, Burch L et al. (1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". J. Nucl. Med. 32 (5): 769–76. PMID 1902508. http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=1902508.
^ Dauer LT, St Germain J, Williamson MJ et al. (2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Phys 92 (1): 33–9. doi:10.1097/01.HP.0000231583.32904.6c. PMID 17164597. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00004032-200701000-00005.

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab^† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8 "-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab^† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab^§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab • Ertumaxomab

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

3F8

See also

References